Myricx Pharma

Therapeutics
Share

Myricx Pharma (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across viral and other diseases.

The Company is based on novel discoveries from the research laboratories of its co-founders, Prof Ed Tate, Dr Roberto Solari and Dr Andrew Bell.  The research teams identified that inhibition of NMT, an enzyme involved in myristoylation of certain proteins, results in specific cancer cell killing via an unexpected and unique mechanism.  This breakthrough discovery reveals that NMT inhibitors are proving to be highly effective in the treatment of MYC-driven cancer models. Until now MYC was considered to be undruggable. Myricx is now prioritising the development of potent small-molecule inhibitors with the aim of building a proprietary pipeline of targeted cancer therapies.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.